Chinese Fosun Pharma Acquired Alma Lasers for $240 Million
29 April, 2013
According to a Harris Williams report, Alma Lasers has a 15% market share in the global high-end medical and beauty laser products industry with annual revenue of about US$100 million
Fosun Pharma will establish Alma Lasers as a management platform for the R&D, manufacturing and sales
The Chinese Medical Devices group, Fosun Pharma, began its expansion into worldwide markets through a multi-million dollars acquisition: Today it announced an agreement to buy the Israeli laser treatment systems provider, Alma Laser for approximately US$240 million.
Alma Lasers is an internationally well-known manufacturer of laser, light-based, radiofrequency and ultrasound products with integrated product portfolios for aesthetic and medical applications. Founded in 1999, the company’s R&D headquarters is situated in Caesarea, Israel and its global support centre is located in Chicago, USA.
Strong Patent Portfolio
According to a Harris Williams report, Alma Lasers has a 15% market share in the global high-end medical and beauty laser products industry with annual revenue of about US$100 million. As of the end of 2012, the near 40-strong R&D team that he leads has 74 patents, and applications for an additional 23 patents. The company entered the China market in 2003 and has since become the leader in this industry.
Mr. Chen Qiyu, Chairman of Fosun Pharma, said, “We are confident in the growth of the global aesthetics industry, especially in China, Brazil, Russia and India. This represents a huge development space in developing countries. We will continue to support the global business development of Alma Lasers.” Fosun Pharma will establish Alma Lasers as a management platform for the R&D, manufacturing and sales of high-end medical devices, providing an internationalized development path for the company.
Fosun Pharma is a leading healthcare company in the PRC. The Group was established in 1994 with headquarters located in Shanghai, and was listed on the Shanghai Stock Exchange in 1998. In October 2012, though the international financial environment was unfavorable, the Company successfully completed offering and listing H shares in Hong Kong.
Posted in: Business , Deals and Investments , Medical , News
Posted in tags: featured